In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bristol pays up to $520mm for immuno-oncology company Cormorant

Executive Summary

Bristol-Myers Squibb Co. acquired Cormorant Pharmaceuticals AB, a private immuno-oncology company founded in 2010, for $95mm in up-front and near-term milestones, plus up to $425mm in development and regulatory earn-outs.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Acquisition of Private Biotech
    • Payment Includes Cash
    • Includes Earnout

Related Companies

Advertisement
UsernamePublicRestriction

Register